Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease

Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease

Source: 
Clinical Trials Arena
snippet: 

Acumen Pharmaceuticals plans to conduct a Phase II or Phase II/III clinical trial investigating the monoclonal antibody ACU193 in patients with early Alzheimer’s disease (AD), says president and CEO Daniel O’Connell. The company expects to initiate the next phase trial in 2024.